Maria Candia-Plata

Dr. Maria Candia-Plata


Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2024 in The American Journal of Tropical Medicine and Hygiene
Verified
Journal Article
Open access
PDF file
GAGERARDO ALVAREZ
GERARDO ALVAREZ
RLRuy López-Ridaura
Ruy López-Ridaura
RCRicardo Cortés-Alcalá
Ricardo Cortés-Alcalá
GRGABRIEL GARCÍA RODRÍGUEZ
GABRIEL GARCÍA RODRÍGUEZ
JCJ R Tadeo Calleja-López
J R Tadeo Calleja-López
DWDavid Walker
David Walker
: Rocky Mountain spotted fever (RMSF) is an ongoing public health crisis in Mexico, particularly in states bordering the United States. The national highest incidence and mortality of RMSF occur in this region, resulting in a case-fatality rate that ranges annually between 10% and 50%, primarily affecting vulnerable groups such as children, elderly adults, and persons living in poverty. Multiple biological, environmental, and social determinants can explain its growing presence throughout the country and how it challenges the health system and society. It is necessary to integrate resources and capacities from health authorities, research centers, and society to succeed in dealing with this problem. Through a scientific symposium, a group of academicians, U.S. health officials, and Mexican health authorities met on November 8–10, 2023, in Hermosillo, Mexico, to discuss the current situation of RMSF across the country and the challenges associated with its occurrence. An urgent call for action to improve national capacity against RMSF in the aspects of epidemiological and acarological surveillance, diagnosis, medical care, case and outbreak prevention, health promotion, and research was urged by the experts. The One Health approach is a proven multidisciplinary strategy to integrate policies and interventions to mitigate and prevent the burden of cases, deaths, and suffering caused by RMSF in Mexico.

1 May 2021 in Obesity Research & Clinical Practice
Verified
Journal Article
Closed access
RVRosa C. Villegas-Valle
Rosa C. Villegas-Valle
ULUnhee Lim
Unhee Lim
GMGertraud Maskarinec
Gertraud Maskarinec
AFAdrian A. Franke
Adrian A. Franke
TEThomas Ernst
Thomas Ernst
JSJohn Shepherd
John Shepherd

1 October 2019 in Nutrients
Verified
Journal Article
Open access
PDF file
BABrianda Ioanna Armenta-Guirado
Brianda Ioanna Armenta-Guirado
TMTeresita Martínez-Contreras
Teresita Martínez-Contreras
MCMaria Candia-Plata
Maria Candia-Plata
JEJulian Esparza-Romero
Julian Esparza-Romero
RMRaúl Martínez-Mir
Raúl Martínez-Mir
Rolando G Diaz-ZavalaRolando G Diaz-Zavala
Rolando G Diaz-Zavala
The Diabetes Prevention Program (DPP) is effective for the prevention of type 2 diabetes by weight loss with diet and physical activity. However, there is little evidence as to whether this program could be translated into real-world clinical practice in Latin American countries. The objective of this work was to evaluate the effectiveness of the DPP for the management of overweightness and obesity at 6 and 12 months in clinical practice in Mexico. This was a non-controlled intervention study implemented in five public clinics in northern Mexico. Two hundred and thirty-seven adults aged 45.7 ± 9.9 years with a Body Mass Index (BMI) of 34.4 ± 5.4 kg/m2 received group sessions with an adaptation of the DPP, in addition to nutrition counseling. One hundred and thirty-three (56%) participants concluded the 6 month phase. They showed a significant weight loss, ranging from 2.76 ± 4.76 to 7.92 ± 6.85 kg (p ≤ 0.01) in the clinics. The intention-to-treat analysis showed a more conservative weight loss. Participant retention at the end of 12 months was low (40%). The implementation of the DPP in different public clinics in Mexico was effective in the management of obesity in the short term, but better strategies are required to improve participant retention in the long term.

1 September 2019 in Diabetes, Metabolic Syndrome and Obesity
Verified
Journal Article
Open access
PDF file
Rolando G Diaz-ZavalaRolando G Diaz-Zavala
Rolando G Diaz-Zavala
MCMaria Candia-Plata
Maria Candia-Plata
TMTeresita de Jesús Martínez-Contreras
Teresita de Jesús Martínez-Contreras
JEJulian Esparza-Romero
Julian Esparza-Romero
Obesity and its comorbidities have become the most important public health problems for Latin America. In Mexico obesity has increased dramatically to the point where the government has declared it an epidemiological emergency. The most recent national data showed overweight and obesity affects 72.5% of adults, or around 56 million Mexicans. Most Mexican adults with obesity are undiagnosed. According to data derived from a national representative survey, only 20% of adults with BMI >30 kg/m2 were diagnosed with obesity by a health provider. Likewise, only 8% of individuals with obesity had received treatment for obesity. Interventions offered in the Mexican health care delivery system generally consist of traditional consultations with recommendations on diet and exercise, visits are monthly to quarterly, and validated behavior change protocols are not used. Evidence from clinical trials has shown that weight loss with this type of treatment is generally less than 1 kg per year. In contrast, intensive lifestyle interventions – protocols focusing on achieving changes in diet, physical activity, and moderate weight loss using behavioral strategies with weekly or bi-weekly sessions for the first 3 to 6 months, and a maintenance phase with trained interventionists – as implemented in the Diabetes Prevention Program and the Look AHEAD studies achieved weight loss of 7–9% at one year. Additionally, translation studies of these interventions to the community and to real-world clinical practice have achieved weight loss of around 4%. Adaptations of intensive lifestyle interventions have been implemented in the United States, both in clinical practice and in the community, and this type of intervention represents a potential model to combat obesity in Mexico and other Latin American countries. It is essential that primary care providers in Mexico implement clinical practice guidelines based on the best evidence available as discussed here to effectively treat obesity. The authors make recommendations to improve the treatment of obesity in the clinical care delivery system in Mexico using intensive lifestyle interventions.

2 March 2024 in Cureus
Verified
Journal Article
Open access
PDF file
JLJesús Andrés López-González
Jesús Andrés López-González
JMJuan Manuel Martínez-Soto
Juan Manuel Martínez-Soto
CACarolina Avila-Cervantes
Carolina Avila-Cervantes
AMAna Lourdes Mata-Pineda
Ana Lourdes Mata-Pineda
GÁGerardo Álvarez-Hernández
Gerardo Álvarez-Hernández
GSGerardo Álvarez-Hernández Sr.
Gerardo Álvarez-Hernández Sr.
Background Diabetes mellitus (DM) is a common comorbidity of active pulmonary tuberculosis (APTB) that increases the risk of treatment failure during anti-tuberculosis chemotherapy. Evaluating systemic inflammatory response could help determine differences in response to treatment between APTB patients and those with APTB and DM. Methodology To explore changes in systemic inflammation, measured by a set of inflammatory mediators in subjects with APTB and TBDM before and after six months of anti-tuberculosis chemotherapy, 30 APTB and nine TBDM subjects underwent cytokine testing, including interleukin (IL)-6, IL-8, IL-10, interferon-gamma (IFN-γ), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta 1 (TGF-β1) by enzyme-linked immunosorbent assay, C-reactive protein by nephelometry, and sialic acid by colorimetric assay at baseline and following six months of standard anti-tuberculosis treatment. Sputum smear microscopy or molecular biology (Xpert MTB/RIF) was used for diagnosis, and sputum smear microscopy was performed monthly during the treatment of the patient with pulmonary tuberculosis to evaluate his evolution. Principal component analysis examined changes in the inflammatory status. Results Both groups showed negative sputum smear microscopy in the sixth month after starting anti-tuberculosis chemotherapy. TGF-β1 was found to be significantly higher in subjects with TBDM before treatment compared to APTB patients (p<0.001), and systemic inflammation continued only in TBDM subjects after treatment (accumulation and persistence of inflammatory mediators like IL-6, IL-8, IL-10, IFN-γ, TNF-α, TGF-β1, C-reactive protein, and sialic acid in blood). On the other hand, the mediators IFN-γ, C-reactive protein, and total sialic acid were found to be most influential in distinguishing pre- and post-treatment inflammatory response in subjects with APTB without DM. Conclusions Inflammatory mediators analyzed in combination, including IFN-γ, CRP, and total sialic acid, may be useful in evaluating the systemic inflammatory response in subjects with APTB and TBDM before and after anti-tuberculosis treatment. Determining these mediators revealed persistent systemic inflammation in TBDM subjects after six months of standard tuberculosis treatment, despite negative sputum smear microscopy results and good glycemic control. This suggests a need for inflammation-modulating therapies during tuberculosis control. Finally, monitoring sputum smear microscopy results alongside the determination of proposed inflammatory mediators (IFN-γ, CRP, and total sialic acid) are effective in evaluating the response to anti-tuberculosis treatment in APTB subjects without DM, warranting further investigation.

26 April 2025 in Cellular and Molecular Biology
Verified
Journal Article
Open access
PDF file
MCMaria Candia-Plata
Maria Candia-Plata
JSJuan Manuel Martínez Soto
Juan Manuel Martínez Soto
JDJeanette Guadalupe Arredondo Damián
Jeanette Guadalupe Arredondo Damián
ARAstrid Nallely Ramírez Romero Ramírez Romero
Astrid Nallely Ramírez Romero Ramírez Romero
LCLucía Guadalupe Villegas Coronado
Lucía Guadalupe Villegas Coronado
JGJosé Manuel Gaván-Moroyoqui
José Manuel Gaván-Moroyoqui
Ferroptosis, an iron-dependent form of regulated cell death characterized by lipid peroxidation, has emerged as a critical process in various diseases. MicroRNAs (miRNAs), small non-coding RNAs that regulate gene expression, are increasingly recognized as key modulators of ferroptosis pathways. This systematic review aims to provide a comprehensive overview of the current knowledge regarding miRNAs implicated in ferroptosis across a spectrum of diseases. We conducted a systematic search of EMBL-EBI, PubMed, Scopus, and Web of Science databases to identify relevant studies published up to October 31, 2022. Our search strategy identified 127 articles encompassing 107 distinct miRNAs that influence ferroptosis. This review synthesizes the findings of these studies, highlighting the specific miRNAs that act as either inhibitors or inducers of ferroptosis in different disease contexts, including various cancers (e.g., lung, breast, colorectal) and degenerative conditions (e.g., acute renal failure, diabetic retinopathy). We discuss the molecular mechanisms by which these miRNAs regulate ferroptosis, often by targeting key genes involved in iron metabolism, lipid peroxidation, and antioxidant defense. Furthermore, we explore the potential of these miRNAs to serve as diagnostic biomarkers and therapeutic targets in ferroptosis-related disorders, offering insights into novel strategies for disease management.